World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
118
Citations
100139
World Ranking
3955
National Ranking
36

Overview

Yi-Long Wu is affiliated with Guangdong Provincial People's Hospital in China and has a primary research focus in Medicine, with extensive work in Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

Their research predominantly addresses topics related to lung cancer, including Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, and Lung Cancer Research Studies. Additional focus areas include Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, and Gastric Cancer Management and Outcomes.

Frequent publication venues for Yi-Long Wu include:

  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • Lung Cancer

Yi-Long Wu has collaborated often with several coauthors throughout their career, particularly with Qing Zhou, Wen-Zhao Zhong, Jin-Ji Yang, Hai-Yan Tu, and Xue-Ning Yang.

Notable recent papers authored or coauthored by Yi-Long Wu include:

  • Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer, 2020, New England Journal of Medicine
  • COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study, 2020, The Lancet Oncology
  • Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC, 2023, New England Journal of Medicine
  • Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial, 2021, Journal of Thoracic Oncology
  • Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial, 2023, Journal of Clinical Oncology

Best Publications

  • Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

    Tony S. Mok;Yi Long Wu;Sumitra Thongprasert;Chih Hsin Yang

  • The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

    Peter Goldstraw;Kari Chansky;John Crowley;Ramon Rami-Porta

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

    Caicun Zhou;Yi Long Wu;Gongyan Chen;Jifeng Feng

  • First-line crizotinib versus chemotherapy in ALK-positive lung cancer

    Benjamin J. Solomon;Tony Shu-kam Mok;Dong Wan Kim;Yi Long Wu

  • Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

    Tony S. Mok;Yi Long Wu;Myung Ju Ahn;Marina C. Garassino

  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski

  • Lung cancer: current therapies and new targeted treatments

    Fred R Hirsch;Giorgio V Scagliotti;James L Mulshine;Regina Kwon

  • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

    Edward S. Kim;Vera Hirsh;Tony Mok;Mark A. Socinski

  • Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

    Yi-Long Wu;Caicun Zhou;Cheng-Ping Hu;Jifeng Feng

  • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

    Tudor Ciuleanu;Thomas Brodowicz;Christoph Zielinski;Joo Hang Kim

  • The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

    Ramón Rami-Porta;David Ball;John Crowley;Dorothy J. Giroux

  • Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

    Masahiro Fukuoka;Yi Long Wu;Sumitra Thongprasert;Patrapim Sunpaweravong

  • Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

    James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian

  • Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

    Yi-Long Wu;Masahiro Tsuboi;Jie He;Thomas John

  • Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

    Alexa B. Turke;Kreshnik Zejnullahu;Yi Long Wu;Youngchul Song

  • First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

    Jean-Charles Soria;Daniel S W Tan;Rita Chiari;Yi-Long Wu

  • Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

    Yi-Long Wu;Ying Cheng;Xiangdong Zhou;Ki Hyeong Lee

  • Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

    James C.H. Yang;Lecia V. Sequist;Sarayut Lucien Geater;Chun Ming Tsai

  • Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer

    T.S. Mok;Y.-L. Wu;M.-J. Ahn;M.C. Garassino

Frequent Co-Authors

Tony Mok
Tony Mok Chinese University of Hong Kong
Caicun Zhou
Caicun Zhou Tongji University
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Li Zhang
Li Zhang Sun Yat-sen University
Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Chong-Jen Yu
Chong-Jen Yu National Taiwan University
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Jianjun Liu
Jianjun Liu Genome Institute of Singapore
Myung-Ju Ahn
Myung-Ju Ahn Sungkyunkwan University
Lecia V. Sequist
Lecia V. Sequist Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a medical career—or looking to expand your expertise—there’s a growing range of online programs that offer flexibility alongside high-quality education. For registered nurses aiming to become nurse practitioners, rn to np programs provide an accelerated pathway to advanced clinical roles without putting your career on hold.

Those interested in nutritional health can pursue online degrees in nutrition, ideal for students hoping to combine health science with public wellness positions. The healthcare sector also demands skilled administrators—cahme accredited mha online programs ensure that future leaders receive reputable, accredited management training.

For RNs seeking career advancement but needing a more flexible approach, rn to bsn without clinicals options allow you to earn a bachelor’s degree in nursing entirely online, removing traditional in-person barriers. These pathways make healthcare education more accessible, supporting career growth in diverse medical roles.

Best Scientists Citing Yi-Long Wu

Trending Scientists